Enphase Energy enters its Q2 earnings print — due July 28 — with short sellers adding to positions, the stock down sharply on the month, and TD Cowen slashing its target just days before the release.
The short interest story is the clearest setup heading into the print. Bears have rebuilt positions over the past week, pushing short interest to nearly 18% of free float — up 5.75% on the week to 23.5 million shares. That marks a reversal from a steadier decline through early-to-mid July, when shorts had pulled back from late-June highs above 27 million shares. Importantly, the lending market isn't restricting this rebuild: availability runs at 253%, meaning there are more than two and a half shares available to borrow for every one already lent out, and the cost to borrow is a negligible 0.40%. That combination — high short interest plus loose borrow conditions — tells you new shorts can enter freely, with no squeeze pressure to act as a brake. Options positioning adds a mild note of caution: the put/call ratio is 0.73, fractionally above its 20-day average, though the z-score of just 0.11 means this is barely a whisper above neutral. The dominant signal here is the short rebuild, not the options market.
The Street's posture is mixed in ways that reflect genuine disagreement about the outlook. TD Cowen's Jeff Osborne cut his target from $70 to $48 on July 20 — just two days before this note — while maintaining a Hold. That's a 31% target reduction with the report six trading days away, and it's the loudest near-term signal from the analyst community. Stepping back, the broader picture is one of gradual rehabilitation: Barclays upgraded the stock in mid-June from Underweight to Equal-Weight, lifting its target from $30 to $51, and Susquehanna moved its target up from $32 to $45 in early July. Goldman Sachs remains the lone Buy from a bulge-bracket name, with a $57 target set in May. The mean target across the group is $48.93 — about 22% above the current $39.94 — but GLJ Research anchors the bear camp with a $21.70 Sell, making the dispersion as wide as the debate. Valuation has compressed materially: the P/E has fallen more than 5 points over the past 30 days, and the P/B multiple has shed over a point in the same period, reflecting the 24% one-month price decline. Factor scores lean bearish — the short score rank is in the 8th percentile and the EPS surprise rank is in the 9th — though the 12-month forward EPS growth rank is in the 93rd percentile, which is the bull camp's key rebuttal.
Insider activity adds a supportive data point, though context matters. CEO Badri Kothandaraman bought 5,000 shares at roughly $67-$68 in late May — a combined ~$337,000 outlay — at prices well above where the stock trades today. That purchase was made into the prior Q1 earnings reaction, when the stock fell 11.5% in a single session before recovering partially over the following five days. The net 90-day insider position is a modest positive at 7,400 shares, and the aggregate is shaped heavily by that CEO buy. It registers as a constructive signal, but buying at $67-68 only to see the stock at $39 is a reminder that conviction from management hasn't been sufficient to stabilise the price.
The earnings history sharpens the stakes for July 28. Last quarter's report produced an 11.5% drop on the day before a partial recovery over the following week. The quarter before that — February 2026 — delivered a 26.8% single-day rally and a 29.4% five-day gain. The pattern is binary: ENPH has an established history of large post-earnings moves in either direction, and with short interest near 18% of float, a positive surprise would put meaningful short-covering pressure into a stock that has already lost nearly a quarter of its value in a month. Close peer SEDG fell 9.5% on the week — nearly in line with ENPH's 11.2% weekly decline — confirming that sector-level pressure is a real component of this move, not just company-specific weakness.
What to watch between now and July 28: whether short interest continues to build toward the late-June highs above 27 million shares, whether any further pre-earnings analyst revisions shift the mean target materially below the current $48.93, and how the stock's earnings history — two starkly divergent reactions in the last two quarters — frames the implied move in options pricing heading into the close on July 28.
See the live data behind this article on ORTEX.
Open ENPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
